62135-803 NDC - ACYCLOVIR

Drug Information

Product NDC: 62135-803

Proprietary Name: Acyclovir

Non Proprietary Name: Acyclovir

Active Ingredient(s):
  • 200 mg/5mL ACYCLOVIR


Administration Route(s): ORAL

Dosage Form(s): SUSPENSION

Pharmacy Class(es):
  • DNA Polymerase Inhibitors [MoA];
  • Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC];
  • Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC];
  • Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor [EPC];
  • Nucleoside Analog [EXT]

Labeler Information

Labeler Name: Chartwell RX, LLC
Product Type: HUMAN PRESCRIPTION DRUG
FDA Application Number: ANDA212718
Marketing Category: ANDA
Start Marketing Date:4/23/2020

Package Information

No. Package Code Package Description Billing Unit
162135-803-47473 mL in 1 BOTTLE (62135-803-47)ML

NDC Record

Field Name Field Value Definition
PRODUCT NDC62135-803Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
PRODUCT TYPE NAMEHUMAN PRESCRIPTION DRUGThis corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
PROPRIETARY NAMEAcyclovirName of Company corresponding to the labeler code segment of the Product NDC.
NON PROPRIETARY NAMEAcyclovirThe non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
DOSAGE FORM NAMESUSPENSION 
ROUTE NAMEORALThe translation of the route code submitted by the firm, indicating route of administration.
START MARKETING DATE4/23/2020 
MARKETING CATEGORY NAMEANDAProduct types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
APPLICATION NUMBERANDA212718This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
LABELER NAMEChartwell RX, LLCName of Company corresponding to the labeler code segment of the Product NDC.
SUBSTANCE NAMEACYCLOVIRAn active ingredient is the substance responsible for the medicinal effects of a product specified by the substance's molecular structure or if the molecular structure is not known, defined by an unambiguous definition that identifies the substance. Each active ingredient name is the preferred term of the UNII code submitted.
ACTIVE NUMERATOR STRENGTH200 
ACTIVE INGRED UNITmg/5mL 
PHARM CLASSESDNA Polymerase Inhibitors [MoA], Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC], Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC], Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor [EPC], Nucleoside Analog [EXT] 

Download Record

Download this NDC record in Text format: Export

Download this NDC record in Excel (CSV) format: Export

Download this NDC record in XML format: Export

This page was last updated on: 4/12/2024